Table 6.
Subgroup analyses
|
Available data |
Number of responders |
p-value a |
Number with disease control |
p-value a | |
|---|---|---|---|---|---|
| n (%) | (CR + PR) | (CR + PR + SD) | |||
|
FcγRIIa polymorphism (N = 27) |
|
|
0.12 |
|
0.19 |
| H/R |
13 (48) |
0 |
|
4 |
|
| H/H |
7 (26) |
1 |
|
2 |
|
| R/R |
7 (26) |
2 |
|
5 |
|
|
FcγRIIIa polymorphism (N = 32) |
|
|
>0.99 |
|
0.72 |
| V/F |
13 (41) |
2 |
|
6 |
|
| F/F |
12 (38) |
1 |
|
4 |
|
| V/V |
7 (22) |
1 |
|
2 |
|
|
DLBCL molecular subtype (N = 27) |
|
|
0.66 |
|
>0.99 |
| GCB |
14 (52) |
1 |
|
4 |
|
| ABC |
11 (41) |
2 |
|
4 |
|
| Other |
2 (7) |
0 |
|
1 |
|
|
CD40 staining intensity (N = 38) |
|
|
0.17 |
|
0.24 |
| 3+ |
22 (58) |
3 |
|
8 |
|
| 2+ |
13 (34) |
0 |
|
7 |
|
| 1+ |
2 (5) |
1 |
|
2 |
|
| 0 |
1 (3) |
0 |
|
0 |
|
|
CD40 expression (N = 38) |
|
|
0.45 |
|
>0.99 |
| ≥2+ and ≥80% positive |
33 (87) |
3 |
|
15 |
|
| <2+ OR <80% positive |
5 (13) |
1 |
|
2 |
|
|
Prior ASCT (N = 43) |
|
|
0.62 |
|
0.75 |
| Yes |
16 (37) |
2 |
|
7 |
|
| No | 27 (63) | 2 | 10 |
aFisher’s exact test.